EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The optical coherence tomography and microperimetry biomarker evaluation in patients with geographic atrophy ( OMEGA ) study: Geographic atrophy progression in fundus autofluorescence ‐ OMEGA report 3

Philippe Valmaggia iD, Georg Ansari iD, Nadja Inglin, Nils Schärer iD, Hanna Zuche iD, Chrysoula Gabrani iD, Faady Yahya, Marco Cattaneo iD, Kristina Pfau iD, Andrea Giani, Marieh Esmaeelpour, Taffeta Chingning Yamaguchi und 6 weitere

Acta Ophthalmologica · 2026

DOI: 10.1111/aos.70119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Ophthalmologica, 2026. Verfasst von Philippe Valmaggia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Geographic Atrophy, Fluorescein Angiography, Tomography, Optical Coherence, Visual Field Tests. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerische Akademie der Medizinischen Wissenschaften, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Boehringer Ingelheim Pharma GmbH & Co. KG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To measure the progression of geographic atrophy (GA) in subjects with age‐related macular degeneration (AMD) in a natural history study.

Methods

We analysed fundus autofluorescence (FAF) images using a semiautomatic method (RegionFinder) to quantify the GA area in a monocentric study. Three independent graders analysed each eye. Patient visits were scheduled at baseline, 12, 24 and 48 weeks. The primary endpoint was the progression of GA area per eye. Potential correlations with clinical and imaging‐based parameters were analysed.

Results

The annual GA progression rate was 1.16 mm 2 /year (95% CI: 0.76–1.56; p < 0.001), with faster growth in eyes with larger baseline lesions ( R 2 = 0.74). After square root transformation, the progression rate was 0.34 mm/year (95% CI: 0.26–0.43; p < 0.001), and the size dependency was reduced (adjusted R 2 = 0.16). Multivariable mixed‐effects models identified a significant association between larger GA lesion sizes per eye and the number of smoking pack‐years ( p = 0.017), the presence of perilesional hyperautofluorescence ( p = 0.044) and a multifocal configuration of the GA lesions ( p = 0.038). Intermediate AMD in the fellow eye was significantly associated with faster GA progression ( p = 0.041).

Conclusion

GA progression in AMD is significantly influenced by baseline lesion size and a larger number of smoking pack‐years is associated with larger GA lesions. The marked variability between individuals underscores the multifactorial nature of GA dynamics. Quantitative FAF analysis is a reliable method for assessing lesion progression and may inform risk‐based monitoring strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Geographic AtrophyFluorescein AngiographyTomography, Optical CoherenceVisual Field TestsVisual FieldsVisual AcuityRetinal Pigment EpitheliumHumansDisease ProgressionFundus OculiFemaleMaleAgedProspective StudiesFollow-Up StudiesBiomarkersAged, 80 and over

Stichwörter der Autor:innen

age‐related macular degenerationdisease progressionfundus autofluorescencegeographic atrophynatural history

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Ophthalmology, University Hospital Basel, Basel, Switzerland.
  • Department of Biomedical Engineering, University of Basel, Allschwil, Switzerland.
  • Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland.
  • Department of Clinical Research, University of Basel, Basel, Switzerland.
  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Vue Eye Center, Biel/Bienne, Switzerland.

ORCID-Profile: Philippe Valmaggia, Georg Ansari, Nils Schärer, Hanna Zuche, Chrysoula Gabrani, Marco Cattaneo, Kristina Pfau, Christian Prünte, Hendrik P N Scholl, Nicolas Feltgen, Leopold Schmetterer, Maximilian Pfau, Peter M Maloca

Förderung

  • Schweizerische Akademie der Medizinischen Wissenschaften
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Boehringer Ingelheim Pharma GmbH & Co. KG

Zitieren

APA

Valmaggia, P., Ansari, G., Inglin, N., Schärer, N., Zuche, H., Gabrani, C., Yahya, F., Cattaneo, M., Pfau, K., Giani, A., Esmaeelpour, M., Yamaguchi, T. C., Prünte, C., Scholl, H. P. N., Feltgen, N., Schmetterer, L., Pfau, M., & Maloca, P. M. (2026). The optical coherence tomography and microperimetry biomarker evaluation in patients with geographic atrophy ( OMEGA ) study: Geographic atrophy progression in fundus autofluorescence ‐ OMEGA report 3. Acta Ophthalmologica. https://doi.org/10.1111/aos.70119

Vancouver

Valmaggia P, Ansari G, Inglin N, Schärer N, Zuche H, Gabrani C, et al. The optical coherence tomography and microperimetry biomarker evaluation in patients with geographic atrophy ( OMEGA ) study: Geographic atrophy progression in fundus autofluorescence ‐ OMEGA report 3. Acta Ophthalmologica. 2026. doi:10.1111/aos.70119

BibTeX
@article{Valmaggia2026,
  author = {Valmaggia, Philippe and Ansari, Georg and Inglin, Nadja and Schärer, Nils and Zuche, Hanna and Gabrani, Chrysoula and Yahya, Faady and Cattaneo, Marco and Pfau, Kristina and Giani, Andrea and Esmaeelpour, Marieh and Yamaguchi, Taffeta Chingning and Prünte, Christian and Scholl, Hendrik P N and Feltgen, Nicolas and Schmetterer, Leopold and Pfau, Maximilian and Maloca, Peter M},
  title = {The optical coherence tomography and microperimetry biomarker evaluation in patients with geographic atrophy ( OMEGA ) study: Geographic atrophy progression in fundus autofluorescence ‐ OMEGA report 3},
  journal = {Acta Ophthalmologica},
  year = {2026},
  doi = {10.1111/aos.70119}
}
Kostenlos starten →